Navigating advanced renal cell carcinoma in the era of artificial intelligence.

Journal: Cancer imaging : the official publication of the International Cancer Imaging Society
PMID:

Abstract

BACKGROUND: Research has helped to better understand renal cell carcinoma and enhance management of patients with locally advanced and metastatic disease. More recently, artificial intelligence has emerged as a powerful tool in cancer research, particularly in oncologic imaging. BODY: Despite promising results of artificial intelligence in renal cell carcinoma research, most investigations have focused on localized disease, while relatively fewer studies have targeted advanced and metastatic disease. This paper summarizes major artificial intelligence advances focusing mostly on their potential clinical value from initial staging and identification of high-risk features to predicting response to treatment in advanced renal cell carcinoma, while addressing major limitations in the development of some models and highlighting new avenues for future research.

Authors

  • Elie J Najem
    Department of Imaging, Dana-Farber Cancer Institute, Boston, MA, USA. elie_najem@dfci.harvard.edu.
  • Mohd Javed S Shaikh
    Department of Imaging, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Atul B Shinagare
    Center for Evidence-Based Imaging, Brigham and Women's Hospital, Boston, Massachusetts; Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: ashinagare@bwh.harvard.edu.
  • Katherine M Krajewski
    Department of Imaging, Dana-Farber Cancer Institute, Boston, MA, USA.